PMA device
NMP22 Elisa Test Kit
Abbott Diagnostics Scarborough, Inc. · System, Test, Tumor Marker, For Detection Of Bladder Cancer (NAH, Class III) · First FDA decision Jun 3, 2008, newest Jun 3, 2008Bladder cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "NMP22 Elisa"
MAUDE reports
0
Brand "NMP22 Elisa", since 2015
PubMed studies
10
Mentioning "NMP22 Elisa"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NMP22 Elisa Test Kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- NMP22 ELISA TEST KITPMA supplement
P940035-S005 · Decided Jun 3, 2008 · 18 days after receipt · Normal 180 Day Track No User Fee
Device type: System, test, tumor marker, for detection of bladder cancer (NAH) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38678WPS Insurance CorporationUpdated Jun 18, 2026
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38584CGS Administrators, LLCUpdated Apr 6, 2026
- Bladder/Urothelial Tumor MarkersLocal determinationIn effectL36975CGS Administrators, LLCUpdated Feb 20, 2026
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLocal determinationIn effectL38643Noridian Healthcare Solutions, LLCUpdated Jan 26, 2026
- Lab: Bladder/Urothelial Tumor MarkersLocal determinationIn effectL36678Noridian Healthcare Solutions, LLCUpdated Oct 27, 2025
- MolDX: Phenotypic Biomarker Detection in Circulating Tumor CellsLocal determinationIn effectL38566Palmetto GBAUpdated Jun 24, 2025
- Lab: Bladder/Urothelial Tumor MarkersLocal determinationIn effectL33420Palmetto GBAUpdated Feb 25, 2021
- Screening for Colorectal Cancer-Non-Invasive Biomarker TestsNational analysisReview closedCAG-00440RUpdated Sep 22, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "NMP22 Elisa", any status and sponsor, newest update first.
No registered device study names "NMP22 Elisa".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NMP22 Elisa", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NAH
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "NMP22 Elisa"[tiab]. The summary above synthesizes these.
- Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y, OʼSullivan P, Raman JD, et al. · Urol Oncol · 2017Clinical Trial, Comparative Study
- [Diagnostic significance of protein NMP22 in bladder cancer].
Rybotycka Z, Dugosz A · Pol Merkur Lekarski · 2015Editorial, English Abstract
- Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
Todenhöfer T, Hennenlotter J, Esser M, et al. · Cancer Cytopathol · 2013
- A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
O'Sullivan P, Sharples K, Dalphin M, et al. · J Urol · 2012Comparative Study, Research Support, Non-U.S. Gov't
- Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
Mian C, Lodde M, Haitel A, et al. · Urology · 2000Comparative Study
- Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
Kelly JD, Dudderidge TJ, Wollenschlaeger A, et al. · PLoS One · 2012Research Support, Non-U.S. Gov't
- [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S, Yamamoto Y, Hosoda S, et al. · Hinyokika Kiyo · 2006English Abstract
- Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
Todenhöfer T, Hennenlotter J, Esser M, et al. · Dis Markers · 2014
- Individual risk assessment in bladder cancer patients based on a multi-marker panel.
Todenhöfer T, Hennenlotter J, Aufderklamm S, et al. · J Cancer Res Clin Oncol · 2013
- [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
Yokoyama T, Sekigawa R, Hayashi T, et al. · Rinsho Byori · 2004Comparative Study, Evaluation Study
Other devices of this type
Also filed under product code NAH.
- NMP22 BladderChek TestAbbott Diagnostics Scarborough, Inc. · PMA 2022
- Alere NMP22 Bladdercheck Test & Control KitAbbott Diagnostics Scarborough, Inc. · PMA 2012
- Alere NMP22 Urine Collection KitAbbott Diagnostics Scarborough, Inc. · PMA 2012
- Matritech NMP22 Test KitAbbott Diagnostics Scarborough, Inc. · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.